updated Tue. October 1, 2024
-
Chicago Tribune
February 1, 2018
It was confirmed; Wittmeyer had Hodgkin's Lymphoma. There was no doubt in Wittmeyer's mind that she would be going home to Elgin, IL to get treatment locally. She knew if she had to have cancer at least this was one which had a treatment that was proven to work. Her mindset: Just Do It. So, she packedÃÂ ...
Lymphoma News Today
January 31, 2018
A new type of T-cell-based cancer immunotherapy may offer hope to people with Epstein-Barr virus-positive Hodgkin's lymphoma, a small clinical trial showed. Importantly, the therapy was designed for use without chemotherapy pretreatment. It was seen to effectively fight tumors without acute or long-termÃÂ ...
Kerrang!
January 30, 2018
Former Suffocation Guitarist Diagnosed With Hodgkin's Lymphoma. Guy Marchais, former guitarist for death metal heroes Suffocation, has been diagnosed with Hodgkin's Lymphoma. Guy Marchais, former guitarist for death metal heroes Suffocation (pictured right in the above photo), has been diagnosedÃÂ ...
Journal of Clinical Pathways
January 29, 2018
According to a research letter published in JAMA Oncology (online January 18, 2018; doi:10.1001/jamaoncol.2017.4887), the risk for breast cancer morbidity differs by subtype in survivors of Hodgkin lymphoma treated with radiotherapy. The risk for breast cancer is known to be relatively high among youngÃÂ ...
Specialty Pharmacy Times
January 25, 2018
In the new dose-escalation study, 8 patients with Epstein Barr virus-positive Hodgkin lymphoma received 2 to 12 doses of specially engineered T cells. The production of transforming growth factor-β (TGF-β) in the tumor microenvironment was found to inhibit targeted therapies by having detrimental effectsÃÂ ...
Healio
January 24, 2018
ATLANTA — Brentuximab vedotin reduced the number of patients with Hodgkin lymphoma who required subsequent treatment, according to results of the phase 3 ECHELON-1 trial presented at the ASH Annual Meeting and Exposition. “Some patients with Hodgkin lymphoma are young and [physicians]ÃÂ ...
Cancer Therapy Advisor
January 24, 2018
Patients treated with BEACOPP have improved outcomes compared with ABVD but also face significant adverse events. A major goal of therapy is therefore to minimize toxicity. A positron emission tomography (PET) outcomes–driven switch in therapy from doxorubicin, vinblastine, vincristine, andÃÂ ...
Healio
January 24, 2018
Risk for ER-negative breast cancer appeared higher among survivors of Hodgkin lymphoma compared with the general population, according to a research letter published in JAMA Oncology. Patients who received radiotherapy for treatment of their Hodgkin lymphoma also had an increased risk forÃÂ ...
Bleacher Report
January 19, 2018
Stanford linebacker Ryan Beecher announced on Friday that he was diagnosed with non-Hodgkin lymphoma last month. "In December, I was diagnosed with non-Hodgkin lymphoma," Beecher wrote on Twitter. "I am receiving treatments while attending classes at Stanford. I look forward to making a full andÃÂ ...
Science Daily
January 16, 2018
They engineered T-cells, essential players in the body's own immune system, to strip tumors of their self-preservation skill and were able to hold Hodgkin lymphoma at bay in patients with relapsed disease for more than four years. What's more, they infused patients with the tumor-directed T-cells withoutÃÂ ...
Healio
January 15, 2018
ATLANTA — A combination of brentuximab vedotin with nivolumab appeared tolerable and safe among patients with relapsed or refractory Hodgkin lymphoma, according to results from a phase 1/phase 2 clinical trial presented at the ASH Annual Meeting and Exposition. An unmet clinical need remains forÃÂ ...
UroToday
January 12, 2018
Lymphoma of urinary bladder is rare and can be primary (0.2% of all bladder neoplasms) or secondary (1.8% of secondary tumors of the bladder), the latter being more common. Here, we report a case each of primary and secondary lymphoma of the bladder who had undergone treatment at our hospital.
The Independent
January 5, 2018
A mum and daughter struck down by cancer just five years apart have been left devastated after a third generation is now suffering with the same disease. Joanne Moss was diagnosed with blood cancer Non-Hodgkin Lymphoma in May 2010, aged 42, but after more than six years of treatment received theÃÂ ...
Cancer Therapy Advisor
January 2, 2018
Dr Dreyling, professor of medicine at the University of Munich Hospital, discusses research presented at the 2017 ASH Annual Meeting likely to have a clinical impact among patients with NHL. Dr Dreyling, MD, PhD, professor of medicine at the University of Munich Hospital in Germany, is a renownedÃÂ ...
Cancer Therapy Advisor
December 26, 2017
For this 2-part phase 1/2 study (ClinicalTrials.gov Identifier: NCT01657331), investigators enrolled 65 patients (98% of whom had Hodgkin lymphoma; 28 patients during stage 1 and 37 during stage 2) who had failed at least 1 previous chemotherapy regimen. Stage 1 of the study was an exploratoryÃÂ ...
Cancer Network
December 18, 2017
Eichenauer gave a presentation on this topic, “Nodular Lymphocyte-Predominant Hodgkin Lymphoma: A Unique Disease Deserving Unique Management,” during an education session at the 2017 American Society of Hematology (ASH) Annual Meeting and Exposition, held December 9–12 in Atlanta.
Cancer Network
December 18, 2017
Eichenauer gave a presentation on this topic, “Nodular Lymphocyte-Predominant Hodgkin Lymphoma: A Unique Disease Deserving Unique Management,” during an education session at the 2017 American Society of Hematology (ASH) Annual Meeting and Exposition, held December 9–12 in Atlanta.
Targeted Oncology
December 12, 2017
Brentuximab Vedotin/Nivolumab Combo Promising for Relapsed/Refractory Hodgkin Lymphoma ... The combination of brentuximab vedotin (Adcetris) and nivolumab (Opdivo) demonstrated promising clinical activity in patients with relapsed/refractory Hodgkin lymphoma (HL), according to results from aÃÂ ...
Targeted Oncology
December 12, 2017
Treatment with the novel PD-1 inhibitor cemiplimab induced responses in half of the patients with Hodgkin lymphoma (HL) in a phase I study of patients with B-lymphoid malignancies; among patients with B-cell non-Hodgkin lymphoma (B-NHL) treated with the monotherapy, the overall response rate (ORR)ÃÂ ...
Targeted Oncology
December 10, 2017
The addition of brentuximab vedotin (Adcetris) to frontline doxorubicin, vinblastine, and dacarbazine (A+AVD) reduced the risk of progression and death by 23% in patients with advanced-stage Hodgkin lymphoma (HL) compared with standard ABVD (doxorubicin [Adriamycin], bleomycin, vinblastine, andÃÂ ...
OncLive
December 9, 2017
The investigational BTK inhibitor zanubrutinib (BGB-3111) demonstrated promising clinical activity in patients with non-Hodgkin lymphoma (NHL), according to findings from a phase Ib study presented at the 2017 ASH Annual Meeting. Among patients with follicular lymphoma (FL), zanubrutinib induced anÃÂ ...
MD Magazine
December 31, 1999
Direct-acting antiviral (DAA) treatment of hepatitis C virus (HCV) infection was well tolerated and appeared synergistic with chemotherapy of comorbid non-Hodgkin's lymphoma (NHL). The risk for NHL is increased with HCV infection, and successful treatment of HCV with pre-DAA era treatments has beenÃÂ ...
Healio
December 31, 1999
ATLANTA — A combination of brentuximab vedotin with ibrutinib appeared tolerable and safe among patients with relapsed or refractory Hodgkin lymphoma, according to results from a phase 2 clinical trial presented at the ASH Annual Meeting and Exposition. “We continue to gain more information aboutÃÂ ...
Pharmacy Today, American Pharmacists Association, pharmacist.com
December 31, 1999
Because up to 30% of advanced Hodgkin's lymphoma patients succumb to refractory disease or relapse after first-line treatment with doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD), researchers tested a new approach. The ECHELON-1 multinational trial randomized 670 treatment-naiveÃÂ ...
OncLive
December 31, 1999
“In this study, we showed that a PET-driven switch from ABVD to escalated BEACOPP can be safely done in advanced-stage Hodgkin lymphoma. With an adequate prolonged follow-up, the final results of this trial showed a 3-year PFS of 82%, three points lower than hypothesized (85%) by the study designÃÂ ...
Journal of Clinical Pathways
December 31, 1999
The National Comprehensive Cancer Network (NCCN) has issued updates to their guidelines for Hodgkin lymphoma, including additions to maintenance therapy options, systemic therapy options, and various treatment algorithms. In the treatment algorithms for classic Hodgkin lymphoma table,ÃÂ ...
Lymphoma News Today
December 31, 1999
The U.S. Food and Drug Administration (FDA) has agreed to review Adcetris (brentuximab vedotin) in combination with chemotherapy as a frontline treatment for patients with advanced Hodgkin's lymphoma, according to Seattle Genetics. The supplemental Biologics License Application was granted priorityÃÂ ...
Curetoday.com
December 31, 1999
Adcetris (brentuximab vedotin) was granted a priority review to a supplemental biologics license application (sBLA) by the Food and Drug Administration (FDA) to be used in combination with Adriamycin, vinblastine and dacarbazine (AVD) to treat patients with classical Hodgkin lymphoma in the frontlineÃÂ ...
News-Medical.net
December 7, 2017
These results can help to find new therapies against T cell Non-Hodgkin's lymphoma triggered by defective immune cells. In the body T cells are usually responsible for immediately detecting and killing cancer cells. However, problems can arise when a T cell itself develops a defect in its genome, the DNA.
Science Daily
December 5, 2017
Cells are also equipped with such 'emergency stop' functions. They make sure that a defective cell doesn't become a tumor cell. A team has now discovered such a switch in T cells. These results can help to find new therapies against T cell Non-Hodgkin's lymphoma triggered by defective immune cells.
WECT-TV6
December 4, 2017
That oncologist was Dr. Justin Markow. He delivered the news to Erskine that he had Non-Hodgkin Lymphoma. "It's difficult to broach that with patients but we do let them know that many patients can live for decades," Markow said. Still, it was bad news for a man who had just started retirement life. "Shock.
StreetInsider.com
November 29, 2017
Hodgkin Lymphoma and T/NK Cell-Lymphoma-Clinical Studies: Hodgkin Lymphoma Immunotherapy studies; nodular lymphocyte predominant ...
Medgadget (blog)
November 29, 2017
HTF MI added a new research study in its database with title 'Non-Hodgkin Lymphoma – Pipeline Review, H2 2017' that includes detailed ...
Lymphoma News Today
November 27, 2017
A new 3D imaging approach for patients with early-stage Hodgkin lymphoma (HL) was better at predicting survival outcomes than standard ...
Research of Market
November 22, 2017
Hodgkin's lymphoma (HL)-Mechanism of action Insights, 2017″, report provides comprehensive insights of the ongoing therapeutic research ...
Healio
November 22, 2017
Radiotherapy prolonged OS among patients with all stages of nodular lymphocytic Hodgkin lymphoma, including those with B-symptoms, ...
Fremont Tribune
November 18, 2017
Fremont High School seniors Hannah Leeper and Preston Reiger pose for a picture Thursday evening inside of the Milady Coffeehouse.
Healio
November 18, 2017
Radiotherapy prolonged OS among patients with all stages of nodular lymphocytic Hodgkin lymphoma, including those with B-symptoms, ...
Lymphoma News Today
November 17, 2017
Nonetheless, the results have convinced Takeda to suggest Adcetris as a new frontline therapy in Hodgkin's lymphoma. Seattle Genetics ...
OncLive
November 16, 2017
Two studies focusing on the role of the metabolic profiles of Hodgkin Lymphoma and Diffuse Large B Cell Lymphoma have been accepted for ...
Cancer Therapy Advisor
November 15, 2017
Two variants of an adjusted regimen used in the treatment classical Hodgkin lymphoma (cHL) achieved comparable rates of complete ...
Oncology Nurse Advisor
November 14, 2017
Among possible PTLD disorders, classical Hodgkin lymphoma (cHL) occurs in only 1.8% to 3.4% of cases. In addition, the incidence of PTLDÂ ...
OncLive
November 2, 2017
The phase III ECHELON-1 trial enrolled 1334 patients with stage III/IV classical Hodgkin lymphoma. All patients had not received prior ...
OncLive
October 28, 2017
The recent breakthrough designation of brentuximab vedotin (Adcetris) for the first-line treatment of patients with classical Hodgkin lymphoma ...
Medgadget (blog)
October 26, 2017
A new research document with title 'Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) Global Clinical Trials Review, H2, 2017' covering ...
Lymphoma News Today
October 26, 2017
CD25 is found in Hodgkin's lymphoma (HL) and many types of NHL, including follicular lymphoma and diffuse large B-cell lymphoma.
Targeted Oncology
October 26, 2017
Nivolumab for classical Hodgkin's lymphoma after failure of both ... with nivolumab in patients with relapsed or refractory Hodgkin lymphoma.
Lymphoma News Today
October 25, 2017
... local radiation) and in combination with MSD's anti-PD-1 agent Keytruda (pembrolizumab) for patients with follicular non-Hodgkin lymphoma.
OncLive
October 25, 2017
Jane N. Winter, MD, professor of medicine, Feinberg School of Medicine, Northwestern University, discusses checkpoint inhibitors for Hodgkin ...
Cancer Network
October 19, 2017
Hodgkin lymphoma patients treated with consolidative proton therapy after chemotherapy had “excellent” early relapse-free survival rates and ...
